An Early Phase 1 interventional study of IVB102 Injection and IVB102 Injection in Retinoschisis, Retinal Disease and Retinal Degeneration, sponsored by InnoVec Biotherapeutics Inc.. Active, not recruiting at 1 site in China. Open to male participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by InnoVec Biotherapeutics Inc. · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.
This is a open label, dose escalation, single-center study. One eye of each participant will receive a single IVB102 injection by intravitreal injection. Participants will be followed for 52 weeks after which they will continue to be followed for up to 5 years after enrollment.
19 studies on the registry are indexed under Retinoschisis; 5 are open to participants now.
This study's planned enrollment of 18 is close to the median of 19 across 12 interventional studies indexed under Retinoschisis.
Browse Retinoschisis studies →InnoVec Biotherapeutics Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraocular injection of a single low dose of IVB102
Genetic: IVB102 Injection
Intraocular injection of a single intermediate dose of IVB102
Genetic: IVB102 Injection
Intraocular injection of a single high dose of IVB102
Genetic: IVB102 Injection
Gene transfer by intravitreal injection of the RS1 AAV vector
Gene transfer by intravitreal injection of the RS1 AAV vector
Gene transfer by intravitreal injection of the RS1 AAV vector
Incidence of DLTs
Number and proportion of dose limited toxicity(DLTs)
Time frame: 4 weeks
Incidence of AEs
Number and severity of overall and ocular Adverse Events (AEs)
Time frame: 52 weeks
Incidence of SAEs
Number and severity of overall and ocular Serious Adverse Events (SAEs)
Time frame: 52 weeks
Visual function
Change from baseline in BCVA(Best Corrected Visual Acuity)(ETDRS)
Time frame: 52 weeks
OCT imaging
Change from baseline in CST(Central Retinal Thickness)(OCT)
Time frame: 52 weeks
ERG parameters
Change from baseline in response amplitudes measured using Electroretinogram (ERG)
Time frame: 52 weeks
Plan to share: No
Ran from Mar 2024 to primary completion in Dec 2025, 21 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InnoVec Biotherapeutics Inc.